Market InstituteMarket Institute
  • About
    • Who We Are
  • Research & Commentary
    • Papers
  • Events
  • Issues
  • Projects
    • International Overreach: When Global Standards Become U.S. Policy
    • Alzheimer’s
    • Letters
    • Political Cartoons

Healthcare

Articles

Surprise billing rules: Is the Biden administration with insurers or doctors and patients?

The Market Institute Charles Sauer is out with a new piece in the Washington Examiner on the issue of surprise billing and how the Biden administration plans on implementing recently passed legislation. “Insurance companies largely won their fight in Congress last year to gain the ability to set the prices Read more…

By admin, 6 years6 years ago
Articles

Possible side effects of government vaccine policies: Less innovation, more deaths

Market Institute President Charles Sauer has a new article in the Washington Examiner on how government interference affects the development of new vaccines. Here’s an excerpt: “Vaccines are now being distributed around the world. However, the process is far from smooth, and many are getting frustrated. They should be. Israel Read more…

By admin, 6 years6 years ago
Articles

Trump enabled the vaccine moonshot, but his drug price rule threatens future innovation

The Market Institute President Charles Sauer has a new piece in the Washington Examiner looking at the White House’s newest proposed regulation on importing foreign prices controls for prescription drugs. Here is an excerpt: “On July 20, 1969, the United States landed on the moon. In November, a couple of Read more…

By admin, 6 years3 years ago
Articles

Republicans Push for Socialist Price Controls in Coronavirus Bill

The Market Institute’s Charles Sauer is out with a new Op-ed in the Washington Examiner looking at legislation on “Surprise Billing.” In the midst of intense negotiations on a phase 4 coronavirus relief bill, a debate is brewing over the inclusion of a ‘fix’ to the issue of surprise billing. Read more…

By Jeff Cargerman, 6 years3 years ago
Articles

Congress wants to Stab Doctors in the Back with ‘Fix’ for Surprise Billing

The Market Institute’s Charles Sauer recently took to the Washington Examiner with a piece on surprise billing legislation. In his words: “Congressmen are talking about backstabbing doctors with a legislative solution that will also undermine our whole healthcare system. Their solution is only supported by the insurance industry and congressmen Read more…

By Jeff Cargerman, 7 years3 years ago

Posts pagination

Previous 1 … 6 7
Recent Articles
  • A Government That’s Trying to Please You Will Make You Miserable October 16, 2026
  • How I Stopped Worrying, and Learned to Love Data Centers October 15, 2026
  • Charles Sauer: Government Policy Is Fueling Hospital Consolidation October 13, 2026
  • Patients First Act: Protecting Choice and Taxpayers October 9, 2026
  • Most Favored Nation Price Controls Disfavor Patients October 5, 2026
Recent Papers
  • The Trouble with Tariffs
  • The $135 Billion Lie: How Upcoding Is Draining Medicare and Medicaid
  • Why Does the Government Pay More for the Same Care?
  • The Practical, Constitutional, and Moral Case Against Social Media Regulation “For the Children”
  • Free Markets Under Attack from the Left and Right

Loading

By adding your phone number, you opt in to receive text messages

Facebook
Twitter
YouTube

The Market Institute Verified account Follow

We promote free market public policies. We get government out of the way.

MarketInstitute
marketinstitute

The Market Institute

Verified account @marketinstitute ·
23 Oct

Businesses should be able to succeed or fail based on how they perform, not how much the government has invested in them. A free market means letting businesses compete on their own, not having the government take a bigger seat at the table.

Stephen Moore @StephenMoore

Memo to the Trump administration: Stop buying companies.

A government $40 trillion in debt should be SELLING assets, not buying ownership stakes in 36 companies.

We thought government control of the means of production was what we were fighting against.

Reply on Twitter 2113667268819182035 Retweet on Twitter 2113667268819182035 Like on Twitter 2113667268819182035 X 2113667268819182035
marketinstitute

The Market Institute

Verified account @marketinstitute ·
23 Oct

The goal should be simple: protect national security without blocking promising medicines from reaching American patients.

Broad biotech restrictions risk doing exactly that.

Axios @axios

Trump administration proposes new curbs on China biotech deals https://www.axios.com/2026/10/23/trump-china-biotech-restrictions?utm_campaign=mrf-utm_source=x&utm_medium=organic_social&utm_campaign=editorial&utm_source=twitter&utm_medium=social&mrfcid=202610236ad04fc1adeaa64e72130b68

Reply on Twitter 2113627990798049521 Retweet on Twitter 2113627990798049521 Like on Twitter 2113627990798049521 X 2113627990798049521
marketinstitute

The Market Institute

Verified account @marketinstitute ·
23 Oct

Protecting inventors is a founding American principle. Strong patent rights give innovators the incentive to build what comes next.

As @newtgingrich puts it:

“We want to encourage inventors. We want to give them legal protection so they have an incentive.”

Reply on Twitter 2113626326032928990 Retweet on Twitter 2113626326032928990 Like on Twitter 2113626326032928990 X 2113626326032928990

  • About
  • Research & Commentary
  • Events
  • Issues
  • Projects